A Study of Ramosetron Plus DX, Dexamethasone, Compared to Granisetron Plus DX for the Prevention of Vomiting and Nausea

Inclusion Criteria: * Subject with age between 20-74 years old (inclusive) of either sex * Cancer subject is scheduled to receive the designated chemotherapy programs * Subject without symptoms of vomiting for at least one week before dosing trial medication * Subject with ECOG performance status scale no greater than 2 * Subject has signed the written informed consent form Exclusion Criteria: * Subject has received radiotherapy to the abdomen or pelvis within 4 weeks before entering this study * Subject has received the designated chemotherapy programs within 6 months before entering the study * Subject has known heart failure or myocardial infraction or with laboratory abnormalities at screening * Subject has known concurrent diseases that may cause vomiting * Subject has taken medications that could influence the outcome of the study within 3 days before entering the study * Subject with a history of allergy or intolerance to ramosetron, granisetron or dexamethasone * Female subject who is pregnant or breastfeeding * Subject with life expectancy less than 3 months * Subject participated other investigational drug trial within 1 month before entering this study